Dr. Frederick is a transplant hepatologist with CPMC’s Liver Disease Management and Transplant Program, and he serves as Director of Clinical Protocols and Liver Support Services. He investigates the pathophysiology and treatment of portal hypertension, hepatic encephalopathy, and liver support devices for acute and acute-on-chronic liver failure.
Author of numerous manuscripts, book chapters, and abstracts, Dr. Frederick leads clinical trials of treatments for hepatic encephalopathy, hepatitis B and C, liver failure, and the management of liver transplantation.
Sutter Health Research Enterprise
2340 Clay Street Floor 3
San Francisco, CA, 94115
(916) 732-4380
fredertz@sutterhealth.org
Primary Research Interests
Related Clinical Trials
AstraZeneca D4326C00003 ZEAL
Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study) (ZEAL)
Investigators: Todd Frederick M.D., Edward Holt MD, Raphael Merriman MD, Kidist Yimam MD
Status: Active, Recruiting
Kezar KZR-616-208 PORTOLA
A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)
Investigators: Todd Frederick M.D., Edward Holt MD, Raphael Merriman MD, Kidist Yimam MD
Status: Active, Recruiting
River2Renal
Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome
Investigators: Todd Frederick M.D., Edward Holt MD
Status: Active, Recruiting
Salix RNLC3131 RED-C-3131
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3131)
Investigator: Todd Frederick M.D.
Status: Active, Not Recruiting